CoChat

The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?

Rodenhizer, Darren, Dean, Teresa, D'Arcangelo, Elisa, McGuigan, Alison P. · 2018 · Advanced Healthcare Materials

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Cancer prognosis remains a lottery dependent on cancer type, disease stage at diagnosis, and personal genetics. While investment in research is at an all‐time high, new drugs are more likely to fail in clinical trials today than in the 1970s. In this review, a summary of current survival statistics in North America is provided, followed by an overview of the modern drug discovery process, classes of models used throughout different stages, and challenges associated with drug development efficiency are highlighted. Then, an overview of the cancer hallmarks that drive clinical progression is provided, and the range of available clinical therapies within the context of these hallmarks is categorized. Specifically, it is found that historically, the development of therapies is limited to a subset of possible targets. This provides evidence for the opportunities offered by novel disease‐relevant in vitro models that enable identification of novel targets that facilitate interactions between the tumor cells and their surrounding microenvironment. Next, an overview of the models currently reported in literature is provided, and the cancer biology they have been used to explore is highlighted. Finally, four priority areas are suggested for the field to accelerate adoption of in vitro tumour models for cancer drug discovery.

Overview

Integrity signals

Registry

Crossref · 10.1002/adhm.201701174

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 257 · Cited by 80

Research works printed but not linked: 12

  1. Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2017, Canadian Cancer Statistics 2017
  2. Jaffee E., 2016, Cancer Moonshot Blue Ribbon Pannel Report
  3. Canadian Cancer Society's Advisory Committee on Cancer Statistics, 1987, Canadian Cancer Statistics 1987
  4. Aitken M., 2016, Global Oncology Trend Report: A Review of 2015 and Outlook to 2020
  5. Pharmaceutical Research and Manufacturers of America, 2016, 2016 Biopharmaceutical Research Industry Profile
  6. Isabella Gashaw K. Z., 2014, Drug Target Rev.
  7. Sittampalam G. S., 2004, Assay Guidance Manual
  8. Michael G., 2013, Perspect. Sci., 1, 56
  9. Caicedo‐Carvajal C. E., 2011, J. Tissue Eng., 2011, 362326
  10. Nakano O., 2001, Cancer Res., 61, 5132
  11. Dangles‐Marie V., 2003, Cancer Res., 63, 3682
  12. West G. W., 1980, Cancer Res., 40, 3665

Metadata

Authors
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P.
Affiliations
  • University of Toronto (CA)
  • Institute of Biomaterials and Biomedical Engineering University of Toronto 200 College Street Toronto M5S 3E5 Canada
Corresponding author
McGuigan, Alison P.
Venue
Advanced Healthcare Materials
Publisher
Wiley
Published
2018-01-19
Volume
7
Issue
8
Pages
e1701174-e1701174
ISSN
  • 2192-2640 (ISSN-L)
  • 2192-2659
OpenAlex
W2791956807
Cited by
80
References
257
Citations by year
2026: 1 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 19 · 2021: 15 · 2020: 11 · 2019: 7 · 2018: 7
FWCI
0.81
Type
journal article
Language
en
Open access
closed
Locations
  • Advanced Healthcare Materials (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research (146469)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
anticancer drug discovery, cancer hallmarks, tumor microenvironment, drug development failure, cancer therapy targets
MeSH terms
Animals, Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Experimental, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? https://app.cochat.ai/papers/10.1002/adhm.201701174
The paper
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018). The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201701174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.